Stemcells Inc (STEM) 1.25 $STEM
StemCells, Inc. Completes Enrollment in Spinal Cord Injury Trial
GlobeNewswire - Thu Apr 17, 7:00AM CDT
StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment in the Company's Phase I/II clinical trial in spinal cord injury. The multi-national, open-label, Phase I/II trial is evaluating both safety and preliminary efficacy of StemCells, Inc.'s proprietary HuCNS-SC(R) human neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve subjects with chest-level injury to the spinal cord. The trial enrolled seven patients with complete paralysis, no motor or sensory function below the point of injury, classified as complete (AIS A), according to the American Spinal Injury Association Impairment Scale, and five patients with no motor function and limited sensory function below the point of injury classified as incomplete (AIS
. Zurich study site principal investigator, Dr. Armin Curt, will present an interim update based on six month data for the first six subjects at the American Spinal Injury Association conference this coming May. Final results from this landmark study are expected to be released mid-2015.
Stock to Watch: StemCells Down 5.3% (STEM)
Comtex SmarTrend(R) - Mon Mar 24, 12:48PM CDT
StemCells (NASDAQ:STEM) is one of today's worst performing low-priced stocks, down 5.3% to $1.42 on 1.0x average daily volume. Thus far today, StemCells has traded 940,000 shares, vs. average volume of 937,000 shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -0.3%) and underperformed the S&P 500 (-5.3% to the S&P's -0.6%) during today's trading.
Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus
PR Newswire - Mon Mar 24, 9:46AM CDT
On Friday, March 20, 2014, the NASDAQ Composite ended at 4,276.79, down 0.98%, the Dow Jones Industrial Average fell by 0.17% to close at 16,302.77, and the S&P 500 finished at 1,866.52, down 0.29%. Four out of ten sectors ended the session in negative. During the session gains in the Utilities, Materials and Energy sectors positively impacted the broader market, while significant retraction came in from Health Care, Consumer Discretionary and Information Technology sectors. The S&P 500 Heath Care Sector Index finished the day at 675.70, down 1.54%, while the same has gained 5.90% in the last three months. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), StemCells Inc. (NASDAQ: STEM), Dendreon Corp. (NASDAQ: DNDN) and Vivus Inc. (NASDAQ: VVUS). Free technical research on EXEL, STEM, DNDN and VVUS can be downloaded upon signing up at:
StemCells, Inc. to Participate at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Wed Mar 19, 7:15AM CDT
StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 13th Annual Needham Healthcare Conference, on Wednesday, April 9, at 8:40 AM EDT at the Westin Grand Central Hotel, 212 East 42nd Street, in New York City. Management is scheduled to present an update on the Company's programs, pipeline and operations.
StemCells, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Business Update
GlobeNewswire - Wed Mar 12, 2:30PM CDT
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2013.
StemCells, Inc. to Participate at 2014 Regen Med Investor Day in New York
GlobeNewswire - Mon Mar 10, 7:00AM CDT
StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the 2nd Annual Regen Med Investor Day, Wednesday, March 26, 2014, at 3:30 pm EDT at the Metropolitan Club, One East 60th Street, in New York City. Mr. McGlynn is scheduled to present an update on the Company's programs, pipeline and operations.
StemCells, Inc. Announces Webcast to Discuss Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Mar 05, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and full year ended December 31, 2013 after the market close on Wednesday, March 12. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day.
Curtiss-Wright Elects Stuart W. Thorn to Board of Directors
GlobeNewswire - Wed Feb 12, 3:15PM CST
Curtiss-Wright Corporation (NYSE:CW) today announced that Stuart W. Thorn has been elected to serve on its Board of Directors.
StemCells, Inc. Announces Completion of the First of Two Cohorts in its Dry Age-Related Macular Degeneration Trial
GlobeNewswire - Wed Feb 12, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment of the first of two planned patient cohorts in the Company's clinical trial of its proprietary HuCNS-SC product candidate (purified human neural stem cells) for dry age-related macular degeneration (AMD). This cohort consisted of eight subjects, four of whom each received 200,000 cells and four of whom each received 1,000,000 cells. The last patient in this cohort was transplanted by Dr. Ted Leng, M.D. Director of Ophthalmic Diagnostics at the Byers Eye Institute at Stanford.
StemCells, Inc. Announces Presentation at Two Upcoming Investor Conferences
GlobeNewswire - Thu Jan 30, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the following conferences:
Investors look to Lighten Up on Shares of StemCells, Shares Down 8.1% (STEM)
Comtex SmarTrend(R) - Mon Jan 27, 10:41AM CST
StemCells (NASDAQ:STEM) is one of today's worst performing low-priced stocks, down 8.1% to $1.36 on 1.0x average daily volume. StemCells has traded 907,000 shares thus far today, vs. average volume of 905,000 shares per day. The stock has underperformed the Dow (-8.1% to the Dow's 0.0%) and underperformed the S&P 500 (-8.1% to the S&P's -0.3%) during today's trading.
StemCells, Inc. Technology is Featured in Canadian TV Broadcast
GlobeNewswire - Mon Jan 13, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that its technology was featured January 10 in a television segment which aired at 10 PM on CTV News Channel and 11 PM on the CTV National News. The story, titled 'Start of stem-cell study offers hope to patients with spinal cord injuries,' includes an interview with the first subject being treated in North America, at the University of Calgary, in StemCells Inc.'s phase I/II clinical trial in spinal cord injury. In addition, Avis Favaro, CTV's medical correspondent, interviews both Dr. Steve Casha, M.D., Ph.D., FRCSC, and Dr. Michael Fehlings M.D., Ph.D., FACS, FRCSC, the two Canadian principal investigators involved in the study.
Hot Stock: StemCells, Shares Gain 6.6% (STEM)
Comtex SmarTrend(R) - Fri Jan 10, 10:12AM CST
StemCells (NASDAQ:STEM) is one of today's best performing low-priced stocks, up 6.6% to $1.54 on 3.0x average daily volume. Thus far today, StemCells has traded 1.9 million shares, vs. average volume of 639,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's -0.2%) and outperformed the S&P 500 (6.6% to the S&P's -0.1%) during today's trading.
StemCells, Inc. Expands Phase I/II Spinal Cord Injury Trial to North America
GlobeNewswire - Fri Jan 10, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that a team at the University of Calgary successfully transplanted its first subject in the Company's Phase I/II clinical trial in chronic spinal cord injury, with the Company's proprietary HuCNS-SC(R) human neural stem cells. The ninth subject to enroll in the trial, which was initiated in Switzerland, is the first spinal cord injury patient to have undergone transplantation in North America. This expansion from a single-site, single-country study to a multi-site, multi-country program accelerates the current trial, which should complete enrollment of the remaining three patients this quarter, and pave the way for a controlled Phase II efficacy study that StemCells, Inc. plans to initiate mid-year to further investigate its HuCNS-SC product candidate as a treatment for spinal cord injury.
StemCells, Inc. to Discuss Plans for Advancing Clinical Studies in Spinal Cord Injury and Age Related Macular Regeneration
GlobeNewswire - Tue Jan 07, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that Eliseo Salinas, M.D., Executive Vice President and Head of Research and Development, will provide an update on the StemCells, Inc. development programs and translational work being done with the Company's proprietary HuCNS-SC(R) human neural stem cells, at the 2014 Alliance for Regenerative Medicine (ARM) State of the Industry Briefing. Dr. Salinas will discuss the Company's plans for completing ongoing safety studies in spinal cord injury and age related macular degeneration (AMD) in the first and second quarters of 2014 respectively, as well as the planned initiation of controlled Phase II efficacy studies in both indications in 2014. The new trials are being designed as definitive Proof of Concept studies with hard clinical outcomes, which should enable the Company to initiate pivotal Phase III studies, assuming that the results are positive. Dr. Salinas is scheduled to speak on January 13th, from 8:00 to 10:00 a.m., at the conference, which is being held at the Parc 55 Wyndham Hotel in San Francisco, CA.
Stock to Watch: StemCells Up 6.2% (STEM)
Comtex SmarTrend(R) - Mon Jan 06, 11:42AM CST
StemCells (NASDAQ:STEM) is one of today's best performing low-priced stocks, up 6.2% to $1.37 on 2.9x average daily volume. Thus far today, StemCells has traded 1.5 million shares, vs. average volume of 506,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's -0.2%) and outperformed the S&P 500 (6.2% to the S&P's -0.3%) during today's trading.
StemCells, Inc. Posts Letter to Shareholders
GlobeNewswire - Mon Jan 06, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn.
StemCells, Inc. Appoints Greg Schiffman as Chief Financial Officer
GlobeNewswire - Thu Nov 14, 8:00AM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, today announced that Greg Schiffman will join its executive team as Chief Financial Officer and Executive Vice President of Finance, effective January 1, 2014. In his new role, Mr. Schiffman will be responsible for all aspects of the Company's financing activities, financial reporting and controls, corporate communications, and investor relations.
StemCells, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
GlobeNewswire - Tue Nov 05, 3:05PM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the third quarter ended September 30, 2013 and provided a business update.
StemCells, Inc. Completes Enrollment in Spinal Cord Injury Trial
GlobeNewswire - Thu Apr 17, 7:00AM CDT
StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment in the Company's Phase I/II clinical trial in spinal cord injury. The multi-national, open-label, Phase I/II trial is evaluating both safety and preliminary efficacy of StemCells, Inc.'s proprietary HuCNS-SC(R) human neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve subjects with chest-level injury to the spinal cord. The trial enrolled seven patients with complete paralysis, no motor or sensory function below the point of injury, classified as complete (AIS A), according to the American Spinal Injury Association Impairment Scale, and five patients with no motor function and limited sensory function below the point of injury classified as incomplete (AIS
. Zurich study site principal investigator, Dr. Armin Curt, will present an interim update based on six month data for the first six subjects at the American Spinal Injury Association conference this coming May. Final results from this landmark study are expected to be released mid-2015. Stock to Watch: StemCells Down 5.3% (STEM)
Comtex SmarTrend(R) - Mon Mar 24, 12:48PM CDT
StemCells (NASDAQ:STEM) is one of today's worst performing low-priced stocks, down 5.3% to $1.42 on 1.0x average daily volume. Thus far today, StemCells has traded 940,000 shares, vs. average volume of 937,000 shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -0.3%) and underperformed the S&P 500 (-5.3% to the S&P's -0.6%) during today's trading.
Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus
PR Newswire - Mon Mar 24, 9:46AM CDT
On Friday, March 20, 2014, the NASDAQ Composite ended at 4,276.79, down 0.98%, the Dow Jones Industrial Average fell by 0.17% to close at 16,302.77, and the S&P 500 finished at 1,866.52, down 0.29%. Four out of ten sectors ended the session in negative. During the session gains in the Utilities, Materials and Energy sectors positively impacted the broader market, while significant retraction came in from Health Care, Consumer Discretionary and Information Technology sectors. The S&P 500 Heath Care Sector Index finished the day at 675.70, down 1.54%, while the same has gained 5.90% in the last three months. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), StemCells Inc. (NASDAQ: STEM), Dendreon Corp. (NASDAQ: DNDN) and Vivus Inc. (NASDAQ: VVUS). Free technical research on EXEL, STEM, DNDN and VVUS can be downloaded upon signing up at:
StemCells, Inc. to Participate at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Wed Mar 19, 7:15AM CDT
StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 13th Annual Needham Healthcare Conference, on Wednesday, April 9, at 8:40 AM EDT at the Westin Grand Central Hotel, 212 East 42nd Street, in New York City. Management is scheduled to present an update on the Company's programs, pipeline and operations.
StemCells, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Business Update
GlobeNewswire - Wed Mar 12, 2:30PM CDT
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2013.
StemCells, Inc. to Participate at 2014 Regen Med Investor Day in New York
GlobeNewswire - Mon Mar 10, 7:00AM CDT
StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the 2nd Annual Regen Med Investor Day, Wednesday, March 26, 2014, at 3:30 pm EDT at the Metropolitan Club, One East 60th Street, in New York City. Mr. McGlynn is scheduled to present an update on the Company's programs, pipeline and operations.
StemCells, Inc. Announces Webcast to Discuss Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Mar 05, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and full year ended December 31, 2013 after the market close on Wednesday, March 12. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day.
Curtiss-Wright Elects Stuart W. Thorn to Board of Directors
GlobeNewswire - Wed Feb 12, 3:15PM CST
Curtiss-Wright Corporation (NYSE:CW) today announced that Stuart W. Thorn has been elected to serve on its Board of Directors.
StemCells, Inc. Announces Completion of the First of Two Cohorts in its Dry Age-Related Macular Degeneration Trial
GlobeNewswire - Wed Feb 12, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment of the first of two planned patient cohorts in the Company's clinical trial of its proprietary HuCNS-SC product candidate (purified human neural stem cells) for dry age-related macular degeneration (AMD). This cohort consisted of eight subjects, four of whom each received 200,000 cells and four of whom each received 1,000,000 cells. The last patient in this cohort was transplanted by Dr. Ted Leng, M.D. Director of Ophthalmic Diagnostics at the Byers Eye Institute at Stanford.
StemCells, Inc. Announces Presentation at Two Upcoming Investor Conferences
GlobeNewswire - Thu Jan 30, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the following conferences:
Investors look to Lighten Up on Shares of StemCells, Shares Down 8.1% (STEM)
Comtex SmarTrend(R) - Mon Jan 27, 10:41AM CST
StemCells (NASDAQ:STEM) is one of today's worst performing low-priced stocks, down 8.1% to $1.36 on 1.0x average daily volume. StemCells has traded 907,000 shares thus far today, vs. average volume of 905,000 shares per day. The stock has underperformed the Dow (-8.1% to the Dow's 0.0%) and underperformed the S&P 500 (-8.1% to the S&P's -0.3%) during today's trading.
StemCells, Inc. Technology is Featured in Canadian TV Broadcast
GlobeNewswire - Mon Jan 13, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that its technology was featured January 10 in a television segment which aired at 10 PM on CTV News Channel and 11 PM on the CTV National News. The story, titled 'Start of stem-cell study offers hope to patients with spinal cord injuries,' includes an interview with the first subject being treated in North America, at the University of Calgary, in StemCells Inc.'s phase I/II clinical trial in spinal cord injury. In addition, Avis Favaro, CTV's medical correspondent, interviews both Dr. Steve Casha, M.D., Ph.D., FRCSC, and Dr. Michael Fehlings M.D., Ph.D., FACS, FRCSC, the two Canadian principal investigators involved in the study.
Hot Stock: StemCells, Shares Gain 6.6% (STEM)
Comtex SmarTrend(R) - Fri Jan 10, 10:12AM CST
StemCells (NASDAQ:STEM) is one of today's best performing low-priced stocks, up 6.6% to $1.54 on 3.0x average daily volume. Thus far today, StemCells has traded 1.9 million shares, vs. average volume of 639,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's -0.2%) and outperformed the S&P 500 (6.6% to the S&P's -0.1%) during today's trading.
StemCells, Inc. Expands Phase I/II Spinal Cord Injury Trial to North America
GlobeNewswire - Fri Jan 10, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that a team at the University of Calgary successfully transplanted its first subject in the Company's Phase I/II clinical trial in chronic spinal cord injury, with the Company's proprietary HuCNS-SC(R) human neural stem cells. The ninth subject to enroll in the trial, which was initiated in Switzerland, is the first spinal cord injury patient to have undergone transplantation in North America. This expansion from a single-site, single-country study to a multi-site, multi-country program accelerates the current trial, which should complete enrollment of the remaining three patients this quarter, and pave the way for a controlled Phase II efficacy study that StemCells, Inc. plans to initiate mid-year to further investigate its HuCNS-SC product candidate as a treatment for spinal cord injury.
StemCells, Inc. to Discuss Plans for Advancing Clinical Studies in Spinal Cord Injury and Age Related Macular Regeneration
GlobeNewswire - Tue Jan 07, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that Eliseo Salinas, M.D., Executive Vice President and Head of Research and Development, will provide an update on the StemCells, Inc. development programs and translational work being done with the Company's proprietary HuCNS-SC(R) human neural stem cells, at the 2014 Alliance for Regenerative Medicine (ARM) State of the Industry Briefing. Dr. Salinas will discuss the Company's plans for completing ongoing safety studies in spinal cord injury and age related macular degeneration (AMD) in the first and second quarters of 2014 respectively, as well as the planned initiation of controlled Phase II efficacy studies in both indications in 2014. The new trials are being designed as definitive Proof of Concept studies with hard clinical outcomes, which should enable the Company to initiate pivotal Phase III studies, assuming that the results are positive. Dr. Salinas is scheduled to speak on January 13th, from 8:00 to 10:00 a.m., at the conference, which is being held at the Parc 55 Wyndham Hotel in San Francisco, CA.
Stock to Watch: StemCells Up 6.2% (STEM)
Comtex SmarTrend(R) - Mon Jan 06, 11:42AM CST
StemCells (NASDAQ:STEM) is one of today's best performing low-priced stocks, up 6.2% to $1.37 on 2.9x average daily volume. Thus far today, StemCells has traded 1.5 million shares, vs. average volume of 506,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's -0.2%) and outperformed the S&P 500 (6.2% to the S&P's -0.3%) during today's trading.
StemCells, Inc. Posts Letter to Shareholders
GlobeNewswire - Mon Jan 06, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn.
StemCells, Inc. Appoints Greg Schiffman as Chief Financial Officer
GlobeNewswire - Thu Nov 14, 8:00AM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, today announced that Greg Schiffman will join its executive team as Chief Financial Officer and Executive Vice President of Finance, effective January 1, 2014. In his new role, Mr. Schiffman will be responsible for all aspects of the Company's financing activities, financial reporting and controls, corporate communications, and investor relations.
StemCells, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
GlobeNewswire - Tue Nov 05, 3:05PM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the third quarter ended September 30, 2013 and provided a business update.
